Aron R. English - 23 Dec 2024 Form 4 Insider Report for Anebulo Pharmaceuticals, Inc. (ANEB)

Signature
/s/ Aron R. English
Issuer symbol
ANEB
Transactions as of
23 Dec 2024
Net transactions value
+$10,000,000
Form type
4
Filing time
26 Dec 2024, 16:15:08 UTC
Previous filing
20 Dec 2024
Next filing
03 Jan 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANEB Common Stock Purchase $10,000,000 +10,101,010 +188% $0.9900 15,467,300 23 Dec 2024 22NW Fund, LP F1, F2, F3
holding ANEB Common Stock 4,654,528 23 Dec 2024 Pharma Investors, LLC F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued to 22NW Fund, LP in connection with a private placement offering of the Issuer.
F2 This Form 4 is filed jointly by Aron R. English and 22NW Fund, LP (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
F3 Securities owned directly by 22NW Fund, LP. Mr. English, as the Manager of 22NW Fund GP, LLC, which is the General Partner of 22NW Fund, LP, may be deemed to beneficially own the securities owned directly by 22NW Fund, LP.
F4 Securities owned directly by Pharma Investors, LLC. Mr. English, as the owner of Pharma Investors, LLC, may be deemed to beneficially own the securities owned directly by Pharma Investors, LLC.